Tirbanibulin Ointment 1%, a Novel Inhibitor of Tubulin Polymerization and Src Kinase Signaling , for the Treatment of Actinic Keratosis (AK): Results from Two Pivotal Phase III Studies

Main Article Content

Andrew Blauvelt
Steven Kempers
Seth Forman
Edward Lain
Suzanne Bruce

Keywords

Actinic Keratosis, Tirbanubulin, topical

Abstract

Abstract not available.

References

1. Fernandez Figueras MT. J Eur Acad Dermatol Venereol . 2017;31 Suppl 2:5 7

2. Smolinksi , MP, et al. J Med Chem . 2018;61:4707 4719

3. DuBois J, et al. Phase I study of tirbanibulin ointment 1%, a novel Src phosphorylation and tubulin polymerization inhibitor, in subjects with actinic keratosis. Poster presented at the 6th Annual Practical Symposium, Beaver Creek, CO, USA, August 8 11, 2019

4. DuBois J, et al. Phase II study of tirbanibulin ointment 1%, a novel Src phosphorylation and tubulin polymerization inhibitor, for actinic keratosis. Poster presented at the 6th Annual Practical Symposium, Beaver Creek, CO, USA, August 8 11, 2019